Skip to main content
Top
Published in: Drug Safety 8/2001

01-07-2001 | Review Article

Drug-Induced Angioedema without Urticaria

Incidence, Prevention and Management

Authors: Dr Angelo Agostoni, Marco Cicardi

Published in: Drug Safety | Issue 8/2001

Login to get access

Abstract

Angioedema without urticaria is a clinical syndrome characterised by self-limiting local swellings involving the deeper cutaneous and mucosa tissue layers. Most occurrences of angioedema respond to treatment with a histamine H1 receptor blocker (antihistamine) because they are an allergic or parallergic reaction. A small number of cases do not respond to antihistamine treatment. Such cases tend to occur in patients with deficiency or dysfunction of the inhibitor of the first component of the complement (C1-INH), but more rarely can occur in patients with other conditions and as an adverse drug reaction.
Angioedema is well documented in patients taking ACE inhibitors. Considering that 35 to 40 million patients are treated worldwide with ACE inhibitors, this drug class could account for several hundred deaths per year from laryngeal oedema. ACE inhibitors certainly do not mediate angioedema through an allergic or idiosyncratic reaction. For this reason the relationship with this drug is often missed and consequently quite underestimated. Rare instances of angioedema have also been reported with angiotensin II receptor antagonists. This adverse effect seems to occur less frequently with angiotensin II receptor antagonists than with ACE inhibitors. However, we do not know whether this adverse effect has the same mechanism with the 2 classes of medications. Some cases of severe angioedema have been recently reported after treatment with fibrinolytic agents. Scattered reports suggest the possibility of angioedema associated with the use of estrogens, antihypertensive drugs other than ACE inhibitors, and psychotropic drugs. Angioedema can also occur with nonsteroidal anti-inflammatory drugs.
Prevention of angioedema relies first on the patient history. Estrogen and ACE inhibitors should be avoided in a patient with congenital or acquired C1-INH deficiency. In the case of ACE inhibitors, the appearance of angioedema following long term treatment does not lessen the probability that such an agent could be the cause. The most important action to take in a patient with suspected drug-induced angioedema is to discontinue the pharmacological agent. Epinephrine (adrenaline), diphenydramine and intravenous methylprednisolone have been proposed for the medical management of airway obstruction, but so far no controlled studies have demonstrated their efficacy. If the acute airway obstruction leads to life-threatening respiratory compromise an emergency cricothyroidotomy must be performed.
Literature
1.
go back to reference Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356(9237): 1255–9PubMedCrossRef Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356(9237): 1255–9PubMedCrossRef
2.
go back to reference World Health Organization. International drug monitoring: the role of national centres: report of a WHO meeting. World Health Organ Tech Rep Ser 1972; 498: 1–25 World Health Organization. International drug monitoring: the role of national centres: report of a WHO meeting. World Health Organ Tech Rep Ser 1972; 498: 1–25
3.
go back to reference Friedmann PS. Assessment of urticaria and angio-oedema. Clin Exp Allergy 1999; 29Suppl. 3: 109–12PubMedCrossRef Friedmann PS. Assessment of urticaria and angio-oedema. Clin Exp Allergy 1999; 29Suppl. 3: 109–12PubMedCrossRef
4.
5.
go back to reference Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 1992; 71(4): 206–15 Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 1992; 71(4): 206–15
6.
go back to reference Binkley KE, Davis III A. Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. J Allergy Clin Immunol 2000; 106(3 Pt 1): 546–50PubMedCrossRef Binkley KE, Davis III A. Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. J Allergy Clin Immunol 2000; 106(3 Pt 1): 546–50PubMedCrossRef
7.
go back to reference Bork K, Barnstedt SE, Koch P, et al. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 2000; 356(9225): 213–7PubMedCrossRef Bork K, Barnstedt SE, Koch P, et al. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 2000; 356(9225): 213–7PubMedCrossRef
8.
go back to reference Warin RP, Cunliffe WJ, Greaves MW, et al. Recurrent angioedema: familial and oestrogen-induced. Br J Dermatol 1986; 115(6): 731–4PubMedCrossRef Warin RP, Cunliffe WJ, Greaves MW, et al. Recurrent angioedema: familial and oestrogen-induced. Br J Dermatol 1986; 115(6): 731–4PubMedCrossRef
9.
go back to reference Cicardi M, Bergamaschini L, Zingale LC et al. Idiopathic nonhistaminergic angioedema. Am J Med 1999; 106(6): 650–4PubMedCrossRef Cicardi M, Bergamaschini L, Zingale LC et al. Idiopathic nonhistaminergic angioedema. Am J Med 1999; 106(6): 650–4PubMedCrossRef
10.
go back to reference Bircher AJ. Drug-induced urticaria and angioedema caused by non-IgE mediated pathomechanisms. Eur J Dermatol 1999; 9(8): 657–63PubMed Bircher AJ. Drug-induced urticaria and angioedema caused by non-IgE mediated pathomechanisms. Eur J Dermatol 1999; 9(8): 657–63PubMed
11.
go back to reference Vleeming W, van Amsterdam JG, Stricker BH, et al. ACE inhibitor-induced angioedema: incidence, prevention and management. Drug Saf 1998; 18(3): 171–88PubMedCrossRef Vleeming W, van Amsterdam JG, Stricker BH, et al. ACE inhibitor-induced angioedema: incidence, prevention and management. Drug Saf 1998; 18(3): 171–88PubMedCrossRef
12.
go back to reference Grossman E, Messerli FH, Neutel JM. Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors? Arch Intern Med 2000; 160(13): 1905–11PubMedCrossRef Grossman E, Messerli FH, Neutel JM. Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors? Arch Intern Med 2000; 160(13): 1905–11PubMedCrossRef
13.
go back to reference Messerli FH, Nussberger J. Vasopeptidase inhibition and angiooedema. Lancet 2000; 356(9230): 608–9PubMedCrossRef Messerli FH, Nussberger J. Vasopeptidase inhibition and angiooedema. Lancet 2000; 356(9230): 608–9PubMedCrossRef
14.
go back to reference Agostoni A, Cicardi M, Cugno M, et al. Angioedema due to angiotensin-converting enzyme inhibitors. Immunopharmacology 1999; 44(1-2): 21–5PubMedCrossRef Agostoni A, Cicardi M, Cugno M, et al. Angioedema due to angiotensin-converting enzyme inhibitors. Immunopharmacology 1999; 44(1-2): 21–5PubMedCrossRef
15.
go back to reference Byrne TJ, Douglas DD, Landis ME, et al. Isolated visceral angioedema: an underdiagnosed complication of ACE inhibitors? Mayo Clin Proc 2000; 75: 1201–4PubMedCrossRef Byrne TJ, Douglas DD, Landis ME, et al. Isolated visceral angioedema: an underdiagnosed complication of ACE inhibitors? Mayo Clin Proc 2000; 75: 1201–4PubMedCrossRef
16.
go back to reference Pellacani A, Brunner HR, Nussberger J. Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects. Clin Sci (Colch) 1994; 87(5): 567–74 Pellacani A, Brunner HR, Nussberger J. Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects. Clin Sci (Colch) 1994; 87(5): 567–74
17.
go back to reference Nussberger J, Cugno M, Amstutz C, et al. Plasma bradykinin in angio-oedema. Lancet 1998; 351(9117): 1693–7PubMedCrossRef Nussberger J, Cugno M, Amstutz C, et al. Plasma bradykinin in angio-oedema. Lancet 1998; 351(9117): 1693–7PubMedCrossRef
18.
go back to reference Sigler C, Annis K, Cooper K, et al. Examination of baseline levels of carboxypeptidase N and complement components as potential predictors of angioedema associated with the use of an angiotensin-converting enzyme inhibitor. Arch Dermatol 1997; 133(8): 972–5PubMedCrossRef Sigler C, Annis K, Cooper K, et al. Examination of baseline levels of carboxypeptidase N and complement components as potential predictors of angioedema associated with the use of an angiotensin-converting enzyme inhibitor. Arch Dermatol 1997; 133(8): 972–5PubMedCrossRef
19.
go back to reference Marcic BM, Erdös EG. Protein kinase C and phosphatase inhibitors block the ability of angiotensin I-converting enzyme inhibitors to resensitize the receptor to bradykinin without altering the primary effects of bradykinin. J Pharmacol Exp Ther 2000; 294(2): 605–12PubMed Marcic BM, Erdös EG. Protein kinase C and phosphatase inhibitors block the ability of angiotensin I-converting enzyme inhibitors to resensitize the receptor to bradykinin without altering the primary effects of bradykinin. J Pharmacol Exp Ther 2000; 294(2): 605–12PubMed
20.
go back to reference Blais Jr C, Rouleau JL, Brown NJ, et al. Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema. Immunopharmacology 1999; 43(2-3): 293–302PubMedCrossRef Blais Jr C, Rouleau JL, Brown NJ, et al. Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema. Immunopharmacology 1999; 43(2-3): 293–302PubMedCrossRef
21.
go back to reference Brown NJ, Ray WA, Snowden M, et al. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther 1996; 60(1): 8–13PubMedCrossRef Brown NJ, Ray WA, Snowden M, et al. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther 1996; 60(1): 8–13PubMedCrossRef
22.
go back to reference Ajayi AA, Adigun AQ. Angioedema and cough in Nigerian patients receiving ACE inhibitors [letter]. Br J Clin Pharmacol 2000; 50(1): 81–2PubMedCrossRef Ajayi AA, Adigun AQ. Angioedema and cough in Nigerian patients receiving ACE inhibitors [letter]. Br J Clin Pharmacol 2000; 50(1): 81–2PubMedCrossRef
23.
24.
go back to reference Gabb GM, Ryan P, Wing LM, et al. Epidemiological study of angioedema and ACE inhibitors. Aust N Z J Med 1996; 26(6): 777–82PubMedCrossRef Gabb GM, Ryan P, Wing LM, et al. Epidemiological study of angioedema and ACE inhibitors. Aust N Z J Med 1996; 26(6): 777–82PubMedCrossRef
27.
28.
go back to reference de Paz S, Martin AB, Iglesias A, et al. Angioedema-urticaria caused by angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists. Med Clin (Barc) 1999; 113(19): 759 de Paz S, Martin AB, Iglesias A, et al. Angioedema-urticaria caused by angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists. Med Clin (Barc) 1999; 113(19): 759
29.
go back to reference Frye CB, Pettigrew TJ. Angioedema and photosensitive rash induced by valsartan. Pharmacotherapy 1998; 18(4): 866–8PubMed Frye CB, Pettigrew TJ. Angioedema and photosensitive rash induced by valsartan. Pharmacotherapy 1998; 18(4): 866–8PubMed
30.
go back to reference Sharma PK, Yium JJ. Angioedema associated with angiotensin II receptor antagonist losartan. South Med J 1997; 90(5): 552–3PubMedCrossRef Sharma PK, Yium JJ. Angioedema associated with angiotensin II receptor antagonist losartan. South Med J 1997; 90(5): 552–3PubMedCrossRef
31.
go back to reference Boxer M. Accupril- and Cozaar-induced angioedema in the same patient. J Allergy Clin Immunol 1996; 98(2): 471PubMedCrossRef Boxer M. Accupril- and Cozaar-induced angioedema in the same patient. J Allergy Clin Immunol 1996; 98(2): 471PubMedCrossRef
32.
go back to reference van Rijnsoever EW, Kwee-Zuiderwijk WJ, Feenstra J. Angioneurotic edema attributed to the use of losartan. Arch Intern Med 1998; 158(18): 2063–5PubMedCrossRef van Rijnsoever EW, Kwee-Zuiderwijk WJ, Feenstra J. Angioneurotic edema attributed to the use of losartan. Arch Intern Med 1998; 158(18): 2063–5PubMedCrossRef
33.
go back to reference Schuster C, Reinhart WH, Hartman K, et al. Angioedema induced by ACE inhibitors and angiotensin II-receptor antagonists: analysis of 98 cases. Schweiz Med Wochenschr 1999; 129: 362–9PubMed Schuster C, Reinhart WH, Hartman K, et al. Angioedema induced by ACE inhibitors and angiotensin II-receptor antagonists: analysis of 98 cases. Schweiz Med Wochenschr 1999; 129: 362–9PubMed
34.
go back to reference Fuchs SA, Koopmans RP, Guchelaar HI, et al. Are angiotensin II receptor antagonists safe in patients with previous angiotensin-converting enzyme inhibitor-induced angioedema? Hypertension 2001; 37(1): U11CrossRef Fuchs SA, Koopmans RP, Guchelaar HI, et al. Are angiotensin II receptor antagonists safe in patients with previous angiotensin-converting enzyme inhibitor-induced angioedema? Hypertension 2001; 37(1): U11CrossRef
35.
go back to reference Sato M, Engelman RM, Otani H, et al. Myocardial protection by preconditioning of heart with losartan, an angiotensin II type 1-receptor blocker: implication of bradykinin-dependent and bradykinin-independent mechanisms. Circulation 2000; 102(19 Suppl. 3): III346–51PubMed Sato M, Engelman RM, Otani H, et al. Myocardial protection by preconditioning of heart with losartan, an angiotensin II type 1-receptor blocker: implication of bradykinin-dependent and bradykinin-independent mechanisms. Circulation 2000; 102(19 Suppl. 3): III346–51PubMed
36.
go back to reference Liu YH, Yang XP, Sharov VG, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure: role of kinins and angiotensin II type 2 receptors. J Clin Invest 1997; 99(8): 1926–35PubMedCrossRef Liu YH, Yang XP, Sharov VG, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure: role of kinins and angiotensin II type 2 receptors. J Clin Invest 1997; 99(8): 1926–35PubMedCrossRef
37.
go back to reference Rudolf J, Grond M, Schmulling S, et al. Orolingual angioneurotic edema following therapy of acute ischemic stroke with alteplase. Neurology 2000; 55(4): 599–600PubMedCrossRef Rudolf J, Grond M, Schmulling S, et al. Orolingual angioneurotic edema following therapy of acute ischemic stroke with alteplase. Neurology 2000; 55(4): 599–600PubMedCrossRef
38.
go back to reference Cooper JP, Quarry DP, Beale DJ, et al. Life-threatening, localized angio-oedema associated with streptokinase. Postgrad Med J 1994; 70(826): 592–3PubMedCrossRef Cooper JP, Quarry DP, Beale DJ, et al. Life-threatening, localized angio-oedema associated with streptokinase. Postgrad Med J 1994; 70(826): 592–3PubMedCrossRef
39.
go back to reference Pancioli A, Brott T, Donaldson V, et al. Asymmetric angioneurotic edema associated with thrombolysis for acute stroke. Ann Emerg Med 1997; 30(2): 227–9PubMedCrossRef Pancioli A, Brott T, Donaldson V, et al. Asymmetric angioneurotic edema associated with thrombolysis for acute stroke. Ann Emerg Med 1997; 30(2): 227–9PubMedCrossRef
40.
go back to reference Walls RM, Pollack Jr CV. Successful cricothyrotomy after thrombolytic therapy for acute myocardial infarction: a report of two cases. Ann Emerg Med 2000; 35(2): 188–91PubMedCrossRef Walls RM, Pollack Jr CV. Successful cricothyrotomy after thrombolytic therapy for acute myocardial infarction: a report of two cases. Ann Emerg Med 2000; 35(2): 188–91PubMedCrossRef
41.
go back to reference Hill MD, Barber PA, Takahashi J, et al. Anaphylactoid reactions and angioedema during alteplase treatment of acute ischemic stroke. CMAJ 2000; 162(9): 1281–4PubMed Hill MD, Barber PA, Takahashi J, et al. Anaphylactoid reactions and angioedema during alteplase treatment of acute ischemic stroke. CMAJ 2000; 162(9): 1281–4PubMed
42.
go back to reference Francis CW, Brenner B, Leddy JP, et al. Angioedema during therapy with recombinant tissue plasminogen activator. Br J Haematol 1991; 77(4): 562–3PubMed Francis CW, Brenner B, Leddy JP, et al. Angioedema during therapy with recombinant tissue plasminogen activator. Br J Haematol 1991; 77(4): 562–3PubMed
43.
go back to reference Caliezi C, Wuillemin WA, Zeerleder S, et al. C1-esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev 2000; 52(1): 91–112PubMed Caliezi C, Wuillemin WA, Zeerleder S, et al. C1-esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev 2000; 52(1): 91–112PubMed
44.
go back to reference Agostoni A, Gardinali M, Frangi D, et al. Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction: a comparison between streptokinase and recombinant tissue-type plasminogen activator. Circulation 1994; 90(6): 2666–70PubMedCrossRef Agostoni A, Gardinali M, Frangi D, et al. Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction: a comparison between streptokinase and recombinant tissue-type plasminogen activator. Circulation 1994; 90(6): 2666–70PubMedCrossRef
45.
go back to reference McGlinchey PG, McCluskey DR. Hereditary angioedema precipitated by estrogen replacement therapy in a menopausal woman. Am J Med Sci 2000; 320(3): 212–3PubMedCrossRef McGlinchey PG, McCluskey DR. Hereditary angioedema precipitated by estrogen replacement therapy in a menopausal woman. Am J Med Sci 2000; 320(3): 212–3PubMedCrossRef
46.
go back to reference Pichler WJ, Lehner R, Spath PJ. Recurrent angioedema associated with hypogonadism or anti-androgen therapy. Ann Allergy 1989; 63(4): 301–5PubMed Pichler WJ, Lehner R, Spath PJ. Recurrent angioedema associated with hypogonadism or anti-androgen therapy. Ann Allergy 1989; 63(4): 301–5PubMed
47.
go back to reference Ponard D, Pernollet M, Richard-Lallemand M-A, et al. Acquired angioedema associated with anti-androgen therapy in a young woman. Exp Clin Immunogenet 1997; 14: 101 Ponard D, Pernollet M, Richard-Lallemand M-A, et al. Acquired angioedema associated with anti-androgen therapy in a young woman. Exp Clin Immunogenet 1997; 14: 101
48.
go back to reference Fujimoto J, Hori M, Itoh T, et al. Danazol decreases transcription of estrogen receptor gene in human monocytes. Gen Pharmacol 1995; 26: 507–16PubMedCrossRef Fujimoto J, Hori M, Itoh T, et al. Danazol decreases transcription of estrogen receptor gene in human monocytes. Gen Pharmacol 1995; 26: 507–16PubMedCrossRef
49.
go back to reference Settipane GA. Adverse reactions of aspirin and related drugs. Arch Intern Med 1981; 141(3 Spec. No): 328–32PubMedCrossRef Settipane GA. Adverse reactions of aspirin and related drugs. Arch Intern Med 1981; 141(3 Spec. No): 328–32PubMedCrossRef
50.
go back to reference Asero R. Leukotriene receptor antagonists may prevent NSAID-induced exacerbations in patients with chronic urticaria. Ann Allergy Asthma Immunol 2000; 85(2): 156–7PubMedCrossRef Asero R. Leukotriene receptor antagonists may prevent NSAID-induced exacerbations in patients with chronic urticaria. Ann Allergy Asthma Immunol 2000; 85(2): 156–7PubMedCrossRef
51.
go back to reference Bavbek S, Celik G, Ediger D, et al. The use of nimesulide in patients with acetylsalicylic acid and nonsteroidal anti-inflammatory drug intolerance. J Asthma 1999; 36(8): 657–63PubMedCrossRef Bavbek S, Celik G, Ediger D, et al. The use of nimesulide in patients with acetylsalicylic acid and nonsteroidal anti-inflammatory drug intolerance. J Asthma 1999; 36(8): 657–63PubMedCrossRef
52.
go back to reference Krikorian RK, Quick A, Tal A. Angioedema following the intravenous administration of metoprolol. Chest 1994; 106(6): 1922–3PubMedCrossRef Krikorian RK, Quick A, Tal A. Angioedema following the intravenous administration of metoprolol. Chest 1994; 106(6): 1922–3PubMedCrossRef
53.
go back to reference Sauve L, Gras-Champel V, Decocq G, et al. Angioedema associated with the use of dihydropyridines [letter]. Therapie 1999; 54(1): 64–5PubMed Sauve L, Gras-Champel V, Decocq G, et al. Angioedema associated with the use of dihydropyridines [letter]. Therapie 1999; 54(1): 64–5PubMed
54.
go back to reference Burches E, Garcia-Verdegay F, Ferrer M, et al. Amiodarone-induced angioedema. Allergy 2000; 55: 1199–200PubMedCrossRef Burches E, Garcia-Verdegay F, Ferrer M, et al. Amiodarone-induced angioedema. Allergy 2000; 55: 1199–200PubMedCrossRef
56.
go back to reference Mithani H, Hurwitz TA. Paroxetine-induced angioedema and tongue swelling. J Clin Psychiatry 1996; 57(10): 486PubMedCrossRef Mithani H, Hurwitz TA. Paroxetine-induced angioedema and tongue swelling. J Clin Psychiatry 1996; 57(10): 486PubMedCrossRef
57.
go back to reference Kimyai-Asadi A, Harris JC, Nousari HC. Critical overview: adverse cutaneous reactions to psychotropic medications. J Clin Psychiatry 1999; 60(10): 714–25PubMedCrossRef Kimyai-Asadi A, Harris JC, Nousari HC. Critical overview: adverse cutaneous reactions to psychotropic medications. J Clin Psychiatry 1999; 60(10): 714–25PubMedCrossRef
58.
go back to reference Schaefer OP, Gore JM. Aspirin sensitivity: the role for aspirin challenge and desensitization in postmyocardial infarction patients. Cardiology 1999; 91(1): 8–13PubMedCrossRef Schaefer OP, Gore JM. Aspirin sensitivity: the role for aspirin challenge and desensitization in postmyocardial infarction patients. Cardiology 1999; 91(1): 8–13PubMedCrossRef
59.
go back to reference Dominguez Ortega J, Robledo T, Martinez-Cocera C, et al. Desensitization to azathioprine. J Investig Allergol Clin Immunol 1999; 9(5): 337–8PubMed Dominguez Ortega J, Robledo T, Martinez-Cocera C, et al. Desensitization to azathioprine. J Investig Allergol Clin Immunol 1999; 9(5): 337–8PubMed
60.
go back to reference McHaourab A, Sarantopoulos C, Stowe DF. Airway obstruction due to late-onset angioneurotic edema from angiotensin-converting enzyme inhibition. Can J Anaesth 1999; 46(10): 975–8PubMedCrossRef McHaourab A, Sarantopoulos C, Stowe DF. Airway obstruction due to late-onset angioneurotic edema from angiotensin-converting enzyme inhibition. Can J Anaesth 1999; 46(10): 975–8PubMedCrossRef
Metadata
Title
Drug-Induced Angioedema without Urticaria
Incidence, Prevention and Management
Authors
Dr Angelo Agostoni
Marco Cicardi
Publication date
01-07-2001
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 8/2001
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200124080-00004

Other articles of this Issue 8/2001

Drug Safety 8/2001 Go to the issue

Leading Article

Thiomersal in Vaccines